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Nasopharyngeal carcinoma (NPC) is a common malignant tumor
in South China. It has been reported that overexpression of antia-
poptotic Bcl-2 family proteins in NPC has caused the lack of long-
term efficacy of conventional therapies. Apogossypolone (ApoG2),
a novel small-molecule inhibitor of antiapoptotic Bcl-2 family pro-
teins, has been discovered as the optimized derivative of gossypol.
In this study, we found that in NPC cells, ApoG2 totally blocked
the antiapoptotic function of Bcl-2 family proteins without affect-
ing the expression levels of these proteins. ApoG2 selectively
inhibited proliferation of 3 NPC cell lines (C666-1, CNE-1 and
CNE-2) that highly expressed the antiapoptotic Bcl-2 proteins.
This inhibitory activity was associated with release of cytochrome
c, activation of caspase-9 and caspase-3 and apoptosis of sensitive
NPC cells. However, ApoG2 had no obvious inhibitory effect on
NPC cell line HONE-1, which expressed antiapoptotic Bcl-2 and
Bcl-xL at a low level. We further found that ApoG2 effectively
suppressed tumor growth of NPC xenografts in nude mice and
enhanced the antitumor effect of CDDP (cisplatin) on NPC cells
in vitro and in vivo. Immunohistochemical results showed that the
expression of CD31 decreased after ApoG2 treatment, which sug-
gested inhibition of angiogenesis in NPC xenografts. Our findings
strongly suggest that ApoG2 may serve as a novel inhibitor of Bcl-
2 family proteins and, by targeting these proteins, may become a
promising drug for the treatment of NPC.
' 2008 Wiley-Liss, Inc.
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Nasopharyngeal carcinoma (NPC) is a kind of squamous cell
carcinoma that occurs in the epithelial lining of the nasopharynx.
Although this malignant disease is rare in Western world, it is
endemic in southern parts of China, Southeast Asia, the Mediterra-
nean basin and Alaska.1 The combination of radiotherapy and ad-
juvant CDDP chemotherapy has become the standard treatment
for NPC,2 but the 5-year survival rate after this treatment is only
about 50–60%, and the rates of 5-year cumulative local relapse
and distant metastasis are 20–30% and 20–25%, respectively.3,4
Etiologic factors identified for NPC include Epstein-Barr virus
(EBV) infection, environmental risk factors (Cantonese-style
salted fish, preserved food, cigarette smoking, as well as use of
Chinese herbs)5 and genetic susceptibility.6
Cancer cells often escape the normal pathways of growth regu-
lation, for example, through oncogene activation, cell cycle check-
point violation and genetic instability. Inhibition of apoptosis is
also considered a requirement of oncogenesis.7 Indeed, antiapop-
totic Bcl-2 family proteins (Bcl-2, Bcl-xL and Mcl-1) are com-
monly highly expressed in many types of cancer.8 Using fluores-
cence in situ hybridization and immunohistochemistry, Bcl-2 was
detected in most (80%) samples of undifferentiated NPC.9 Fan
and colleagues found that expression of Bcl-2 protein was signifi-
cantly higher in NPC tissues than in normal noncancerous naso-
pharyngeal epithelia (NPE) and hyperplastic NPE.10 Latent EBV
infection is detected in NPC cells of virtually all patients in
endemic regions.11 NPC cells consistently harbor EBV DNA and
some EBV proteins, including latent membrane protein 1 and
BARF1, which can upregulate Bcl-2 and Mcl-1 to protect host
cells from apoptosis.12,13 Overexpression of antiapoptotic proteins
decreases proapoptotic response and results in resistance of NPC
cells to traditional radiation and chemical therapies.14 A recent
report has shown that a Bcl-2 antisense oligodeoxynucleotide,
G3139, has proapoptotic effects in the NPC cell line C666-1 and
in combination with CDDP leads to regression of C666-1 xeno-
grafts.15 Cumulatively, these studies suggest that antiapoptotic
Bcl-2 family proteins may represent a biologically relevant target
for the development of novel therapies for NPC.
The Bcl-2 family contains critical regulators of the mitochon-
drial pathway of apoptosis.16 Based on functions and regions of
the Bcl-2 homology (BH) domain, this family is subdivided into 3
main groups: multidomain antiapoptotic proteins (Bcl-2, Bcl-xL,
Mcl-1 and Bfl-1/A1), multidomain proapoptotic proteins (Bax and
Bak) and BH3-only proapoptotic proteins (Bid, Bim, PUMA and
NOXA). The BH3 domain is an amphipathic a-helix that interacts
with the multidomain family members through binding to the
hydrophobic cleft formed by the BH1, BH2 and BH3
domains.17,18 A study of the experimental structure of Bcl-xL
showed that its BH1, BH2 and BH3 domains form a hydrophobic
binding groove (the BH3-binding groove) into which the BH3 do-
main of Bax/Bak or PUMA/NOXA binds.19 The BH3-binding
pocket of multidomain antiapoptotic members is essential for their
function. It has been hypothesized that small molecules that bind
to the BH3-binding pocket may be capable of blocking the hetero-
dimerization of antiapoptotic and proapoptotic proteins and in turn
may trigger apoptosis. Several recent studies have shown that
using computational screening and structure-based design, it is
possible to discover and design potent, nonpeptidic small-mole-
cule inhibitors that bind to the BH3-binding pocket.20–22 One such
molecule is gossypol, a polyphenol isolated from the seed, stem
and roots of the cotton plant (Gossypium).23
Gossypol has been successfully used as a contraceptive drug for
men in China for more than 35 years.24 In 1984, Tuszynski and
Cossu25 found that gossypol has antitumor effects against mela-
noma and colon carcinoma Since then, many observations have
been reported on gossypol’s antiproliferative activity against tu-
mor cells, such as human colon carcinoma cells,26 head and neck
squamous cell carcinoma cells,27 diffuse large cell lymphoma
cells28 and prostate cancer cells.29 Moreover, many efforts have
been made to optimize this molecule’s structure and improve its
antitumor efficacy. Apogossypol overcomes the steric hindrance
of gossypol because it lacks 2 aldehyde groups,30 and compared
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with gossypol, it showed superior efficacy with less toxicity in
Bcl-2 transgenic mice.31 Gossypolone, the oxidation product of
gossypol, has been found to be more cytotoxic than gossypol and
other derivatives.32 Based on these findings, apogossypolone
(ApoG2), the oxidation product of apogossypol, was synthesized.
In a previous reported study, a fluorescence polarization-based
binding assay showed that ApoG2 is a small-molecule inhibitor of
antiapoptotic Bcl-2 proteins that was predicted to bind to these
family proteins with higher affinity and to exhibit much higher
antitumor activity than gossypol.33
The purpose of this study was to evaluate whether ApoG2 is a
potent inhibitor of antiapoptotic Bcl-2 family proteins and whether
it possesses antitumor activity in NPC cell lines and in animal
models. We also assessed the related molecules involved in
ApoG2-induced cell death. We found that ApoG2 indeed induced
apoptosis by blocking the antiapoptotic functions of Bcl-2 family
members. In vivo, ApoG2 alone or combined with CDDP effec-
tively inhibited NPC tumor growth in nude mice.
Material and methods
Cells, compound preparation and affinity
Human NPC cell lines CNE-1 (a highly differentiated NPC cell
line), CNE-2 (a poorly differentiated NPC cell line), HONE-1
(also a poorly differentiated NPC cell line) and C666-1 (a NPC
cell line infected with EBV) were all originally obtained from
NPC patients and maintained in our laboratory in RPMI 1640
(Gibco/Invitrogen, Gaithersburg, MD) supplemented with 10%
heat-inactivated fetal bovine serum (HyClone/Thermo Fisher Sci-
entific, Logan, UT). Cells were incubated in a humidified 5% CO2
atmosphere at 37C. ApoG2 was synthesized by Professor Dajun
Yang and dissolved in pure dimethyl sulfoxide (DMSO) with a
stock concentration of 20 mmol/L; the solution was stored at
220C. ABT-737, also supplied by Professor Dajun Yang, was
dissolved in DMSO for in vitro experiments.
In in vivo experiments, for intragastric administration, ApoG2
was suspended in 0.5% sodium carboxymethylcellulose; CDDP
was diluted in sterile normal saline solution. All dose formulations
were prepared on the day of use.
MTT assay
Cell viability was measured by 3-[4,5-dimethylthiazol-2-thia-
zolyl]-2,5-diphenyltetrazolium bromide (MTT) assay, based on
mitochondrial conversion of MTT from soluble tetrazolium salt
into an insoluble colored formazan precipitate, which was dis-
solved in DMSO and quantitated by spectrophotometry (Thermo
Multiskan MK3; Thermo Labsystems, Vantaa, Finland) to obtain
optical density (OD) values.34 NPC cells were plated in 96-well
culture clusters (Costar, Cambridge, MA) at a density of 15,000–
25,000 cells /mL. Serial dilutions were made from stock solution
of ApoG2 or CDDP to desired concentrations. All experimental
concentrations were replicated in triplicate. Four hours before
desired time points, 10 lL of 10 mg/mL MTT was added. Then,
after incubation for 4 hr, the plates were depleted, and 100 lL
DMSO was added. The percentages of absorbance relative to
those of untreated control samples were plotted as a linear func-
tion of drug concentration. The 50% inhibitory concentration
(IC50) was identified as the concentration of drug required to
achieve 50% growth inhibition relative to untreated control popu-
lations. Inhibition of cell growth was measured by percentage of
viable cells relative to the control: % inhibition 5 100% 3 ODT/
ODC, where ODT is the average OD value of the treated samples
and ODC is the average OD value of the control samples.
Moreover, to study the effect of ApoG2 in combination with
CDDP, we used Calcusyn software35 (Biosoft, Cambridge, UK) to
calculate the combination index (CI) values for each concentration
tested, whereby CI values less than 1 indicate synergy, a CI value
equal to 1 indicates additivity, and those greater than 1 indicate
antagonism in the interaction of the drugs.
Detection of cell apoptosis
ApoG2-induced apoptosis in NPC cells was evaluated by 4,6-
diamidine-2-phenylindole (DAPI) nuclear staining. Cells were
cultured in 6-well cell culture clusters and exposed to ApoG2. For
fluorescence microscopic examination, cells were fixed with 10%
absolute methanol permeabilized by 0.5% Triton X-100 and
stained with DAPI (2 lg/mL) for 30 min at 37C. The morpho-
logic changes of apoptosis-characteristic nuclei were examined by
fluorescence microscopy (DFC480; Leica Microsystems, Wetzlar,
Germany).
ApoG2-induced apoptosis was also detected by a DNA ladder-
formation assay following the method of Laird et al.36 Briefly, af-
ter treatment with ApoG2 at desired concentrations and time inter-
vals, cells were harvested, washed and incubated with lysis buffer
(10 mM Tris-HCl [pH 8.5], 5 mM ethylenediamine tetraacetic
acid [EDTA], 0.2% sodium dodecyl sulfate [SDS], 0.2 M NaCl,
0.1 mg/mL proteinase K) for 2 hr. DNA was extracted by mixing
the cell lysates with an equal volume of isopropanol. Then the
lysates were centrifuged, and the pelleted DNA was air dried and
resuspended in 10 lL of 10 mM Tris-HCl with 0.1 mM EDTA
(pH 7.5). Complete dissolution of DNA was effected by overnight
agitation at 55C. DNA was resolved over 0.8% agarose gel
stained with ethidium bromide after gel electrophoresis. The bands
were visualized under a UV transilluminator (Bio-Rad Laborato-
ries, Hercules, CA).
Cell cycle analysis
About 5 3 106 cells were harvested, fixed with 70% ethanol
and incubated overnight at 220C. Cells were then washed and
resuspended in 300 lL of staining solution (100 lg/mL propidium
iodide [PI], 0.5 mg/mL RNase and 0.08 mg/mL proteinase inhibi-
tors) for 30 min. The PI fluorescence associated with DNA was
measured by flow cytometer (Beckman Coulter, Fullerton, CA).
The percentages of nuclei in each phase (G1, S, G2/M) of the cell
cycle were calculated by MultiCycle software (Phoenix Flow Sys-
tems, San Diego, CA). Analysis of apoptotic cells (percentage of
subdiploid cells) was carried out with WinMDI 2.9 software in-
stalled on the flow cytometer.
Isolation of cytosol and mitochondrial fractions
NPC cells were exposed to 10 lM ApoG2 for 0–72 hr, col-
lected, washed with PBS and suspended in 5 volumes of chilled
buffer A (250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM
MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DL-dithiothreitol
[DTT], 17 lg/mL phenylmethylsulfonyl fluoride [PMSF], 8 lg/
mL aprotinin and 2 lg/mL leupeptin [pH 7.4]) on ice for 15 min.
Cell fractionation was done as previously described.37 Briefly,
cells were homogenized using an ice-cold cylinder cell homoge-
nizer (20–25 strokes). Cellular and nuclear debris were removed
by centrifuging the homogenates twice at 750g for 10 min. The
supernatants were pelleted again at 10,000g for 25 min. The re-
sultant mitochondrion pellets were resuspended in 1 volume of
chilled buffer A. The supernatants were further centrifuged at
100,000g for 1 hr; the resultant supernatants were the cytosolic
fraction.
Detection of caspase activity by spectrophotometry
To examine the ApoG2-induced activation of the caspase cas-
cade, caspase colorimetric assay kits (BioVision, Mountain View,
CA) and a spectrophotometer (Thermo Multiskan MK3) were
used. The assay was based on spectrophotometric detection of the
chromophore p-nitroanilide (pNA) after cleavage from the labeled
caspase substrate DEVD-pNA. The pNA light emission was quan-
tified using a spectrophotometer at 400 or 405 nm. Comparison of
the absorbance of pNA from an apoptotic sample to that of an
uninduced control allowed determination of the extent of increase
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in caspase activity. After treatment with ApoG2, NPC cells were
collected, washed and incubated in 50 lL lysis buffer on ice for
20 min. Then 50 lL of 23 reaction buffer was added to cell
lysates with a concentration equal to 100 lg proteins/50 lL. Next,
5 lL of labeled substrates was added, and the solution was incu-
bated in the dark at 37C for 4 hr. Activation of caspases was
measured by the OD values obtained by spectrophotometer at a
wavelength of 405 nm.
Immunoblot and immunoprecipitation analysis
Protein analyses by immunoblots and immunoprecipitations
were performed as previously described38 with primary antibodies
against Bcl-2 (clone Bcl-2-100; Sigma-Aldrich. St. Louis, MO),
Bcl-xL (#2762; Cell Signaling Technology, Danvers, MA), Mcl-1
(sc-819; Santa Cruz Biotechnology, Santa Cruz, CA) Bax (#2772;
Cell Signaling), Bak (#AM04; EMD Biosciences, San Diego,
CA), PUMA (#4976; Cell Signaling), NOXA (sc-26917; Santa
Cruz), cytochrome c (#4272; Cell Signaling), caspase-3 (#9662;
Cell Signaling) and actin (clone AC-15; Sigma-Aldrich). Total
cell lysates were harvested, electrophoresed by 12% SDS-poly-
acrylamide gel electrophoresis (PAGE) and then transferred to
polyvinylidene difluoride membranes (Roche, Basel, Switzerland).
Immunoblotting involved incubation with the primary antibodies
listed earlier, followed by addition of secondary antibodies conju-
gated to horseradish peroxidase (Cell Signaling) to facilitate
detection and addition of enhanced chemiluminescence reagent
(Cell Signaling) to develop the blots.
Dajun Yang et al.33 have reported that ApoG2 potently binds to
Bcl-2 and Mcl-1 in a fluorescence polarization-based assay. To
test whether ApoG2 occupies the BH3-binding pocket of Bcl-2
and thereby blocks the binding of Bcl-2 and Bax in NPC cells,
immunoprecipitations were performed using the Catch and
Release v2.0 Kit (Upstate, Charlottesville, VA) following the kit
recommendations. Cell lysates were incubated with antibodies of
antiapoptotic proteins, antibody capture affinity ligand and protein
G agarose beads at 4C overnight on a rotator. Proteins bound to
the beads were eluted by denaturing elution buffer, separated by
SDS-PAGE and immunoblotted with antibodies of proapoptotic
proteins to identify the binding of Bcl-2 family proteins. To con-
firm the results, we also precipitated cell lysates with antibodies of
proapoptotic antibodies and then did Western blots with antibodies
of antiapoptotic proteins.
In vivo treatment, immunohistochemistry
and TUNEL staining assay
Four-week-old athymic nude (nu/nu) mice obtained from the
Animal Center of Southern Medical University (Guangdong,
China) received subcutaneous injection of 1 3 107 CNE-1 or
CNE-2 cells in each axillary area. Based on our laboratory’s pol-
icy, when subcutaneous tumors developed to more than 1,500 mg,
mice were euthanized and tumors were dissected and mechani-
cally dissociated into equal pieces to be transplanted into the flank
areas of a new group of mice. Mice were checked every day
for xenograft development. When tumors became palpable (about
0.1 mm3), mice were randomly divided into 4 groups. Each group
contained 8 mice, and there was no difference in tumor size
between groups. Using this model, we studied the efficacy of
ApoG2 alone (200 mg/kg of body weight given by intragastric
administration daily), CDDP alone (3 mg/kg of body weight by in-
traperitoneal injection once every 2 days) and the combination of
ApoG2 (200 mg/kg of body weight given by intragastric adminis-
tration daily) and CDDP (3 mg/kg of body weight by intraperito-
neal injection once every 2 days). Tumor volumes and body
weight of mice were observed. The end points for assessing antitu-
mor activity were the standard measurements used in our labora-
tory: tumor volume (mm3)5 (A 3 B2)/2, where A and B represent
the tumor length and width (in mm), respectively. Tumor growth
inhibition (T/C %), used to evaluate the tumor response to the
drugs, was calculated using the ratio of the average tumor weight
of the treated group (T) to the average tumor weight of the control
group (C).
Immunohistochemical analysis and terminal deoxynucleotidyl
transferase biotin-dUTP nick end labeling (TUNEL) staining were
performed on tissue-sample sections of CNE-2 xenografts
obtained from 4 treatment groups: saline solution (control),
ApoG2, CDDP and their combination. All samples were stained
with hematoxylin and eosin and microscopically examined to con-
firm the NPC cell origin. Sections were deparaffinized and rehy-
drated using xylene and alcohol. Sections were then stained with
Bcl-xL (#2762; Cell Signaling), PUMA (#4976; Cell Signaling)
and CD31 (sc-1506; Santa Cruz) at 4C overnight or for TUNEL
at 37C for 60 min. All antibodies and TUNEL labels were visual-
ized using diaminobenzidine (DAB) (DAKO Liquid DAB, Dako,
Carpinteria, CA) as peroxidase substrates. TUNEL-positive nuclei
were stained brown (DAB) and all other nuclei were stained
blue.39
Two skilled pathologists independently reviewed the slides and
recorded the proportion of stained cells in each treatment group.
The evaluation of protein expression was assessed semiquantita-
tively by staining intensity as negative, weakly positive or strongly
positive according to Carcangiu et al’s method.40
Results
ApoG2 potently binds to antiapoptotic Bcl-2 family proteins
and blocks the binding of antiapoptotic Bcl-2 family
proteins and proapoptotic Bcl-2 family proteins
The chemical structures of gossypol and its optimized deriva-
tive, ApoG2, are presented in Figure 1a. It is well known that the
antiapoptotic functions of Bcl-2 and Bcl-xL are based on their het-
erodimerization with proapoptotic Bcl-2 family proteins, such as
Bax and Bak.41 To test the hypothesis that ApoG2 inhibits the
function of Bcl-2 and Bcl-xL by blocking heterodimerization of
Bcl-2 and Bax and heterodimerization of Bcl-xL and Bak, immu-
noprecipitation assays were performed. As shown in Figure 1b, in
untreated CNE-2 cells, both antiapoptotic proteins (Bcl-2 and Bcl-
xL) and proapoptotic proteins (Bax and Bak) were expressed
(Lane 1) and bound to each other (Lane 2). However, when cells
were exposed to 10 lM ApoG2 for 48 hr, the Bcl-2/Bax binding
and Bcl-xL/Bak binding were totally interrupted (Lane 3). The
Bcl-2 levels in Bax-precipitated cells in the absence of ApoG2
were lower than Bcl-2 levels in cell lysates (Fig. 1b), which was
expected because Bcl-2 protein is able to bind to a variety of non-
Bcl-2 family proteins, such as P53, Raf-1 and Ras.42 The same sit-
uation was also observed in Bak-precipitated cells.
Protein expression level of Bcl-2 family members in NPC cell lines
and effects of ApoG2 on these proteins
Since Bcl-2 family proteins had been shown to be targets of
ApoG2, we further investigated the expression level of these pro-
teins in NPC cells. We used MCF7, a breast cancer cell line in
which the antiapoptotic Bcl-2 proteins are highly expressed,43 as a
positive control. As shown in Figure 1c, the expression levels of
Bcl-2 family proteins were different among 4 NPC cell lines. In
C666-1 cells, antiapoptotic proteins Bcl-2, Bcl-xL and Mcl-1L
were all expressed high level, whereas levels of proapoptotic pro-
teins Bax and Bak were extremely low. CNE-1 and CNE-2 cells
both expressed antiapoptotic Bcl-xL and Mcl-1L at a high level.
However, in HONE-1 cells, only Mcl-1L was expressed at a high
level compared with the level in MCF7 cells. Concerning the
proapoptotic proteins, van Delft et al.44 demonstrated that the cy-
totoxic activity of gossypol did not depend on Bax or Bak.
Actually, Bax and Bak were not the only proapoptotic Bcl-2 fam-
ily proteins expressed in NPC cells; other BH3 proteins, such as
PUMA, were also expressed.
Next, we assessed whether ApoG2 could modulate the protein
expression levels of Bcl-2 family members in NPC cells. To do
so, we used bortezomib, a potent proteasome inhibitor that previ-
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ously was able to induce mitochondria-dependent apoptosis by
regulating Bcl-2 family proteins, such as NOXA, Mcl-1 and Bik,
in cancer cells.34,45,46 We found that bortezomib inhibited growth
of NPC cell lines (Supplementary Fig. S1) and regulated the
expression level of Mcl-1L, PUMA and NOXA in CNE-2 cells
(Fig. 1d). We used bortezomib as a positive agent to test whether
ApoG2 also affected the expression level of Bcl-2 family proteins.
As shown in Figure 1d, compared with untreated cells, we
observed no significant alteration of expression levels of Bcl-2
family proteins after treatment with 10 lM ApoG2 for 12, 24 and
48 hr; only NOXA was induced at 12 hr after treatment.
ApoG2 treatment inhibits NPC cell survival in vitro
The effect of ApoG2 on cell survival was evaluated by MTT
assay. NPC cell lines C666-1, CNE-1, CNE-2 and HONE-1 were
exposed to 0–20 lM ApoG2 for 24, 48 and 72 hr. As shown in
Figure 2a, exposure to ApoG2 resulted in dose- and time-depend-
FIGURE 1 – ApoG2 and its targets in NPC cell lines. (a) The chemical structures of gossypol and its derivative compound apogossypolone
(ApoG2). ApoG2, an oxidation product of gossypol, lacks 2 aldehyde groups. (b) Inhibition of the binding of Bcl-2 and Bax by ApoG2 in vitro
in CNE-2 cells. CNE-2 cells (1 3 106) were treated with 10 lM ApoG2 for 48 hr. Immunoprecipitation assays were performed as described in
Material and Methods. CNE-2 cell lysates (Lane 1) served as a positive control; immunoprecipitation wash buffer (Lane 4) served as a negative
control. Cell lysates of untreated (Lane 2) and ApoG2-treated CNE-2 cells (Lane 3) were immunoprecipitated by primary anti-Bax or anti-Bcl-2
antibodies. Western blots were performed to demonstrate whether ApoG2 treatment affected the binding of Bax and Bcl-2. (c) Western blots
show the expression level of Bcl-2 family members in NPC cell lines. MCF7 served as a positive control. Data shown are 1 representation of 3
independent experiments. (d) The effect of ApoG2 on levels of expression of Bcl-2 family proteins. Bortezomib, which regulates the expression
level of some Bcl-2 family proteins in cancer cells, served as a positive control. CNE-2 cells were exposed to 10 lM ApoG2 or 50 nM bortezo-
mib for 12, 24 and 48 hr. DMSO treatment for 24 hr served as negative-control treatment (NT). Whole-cell extracts were analyzed with Western
blots. Actin reprobing comfirmed equal loading of the total protein. Data shown are 1 representation of 3 independent experiments.
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ent inhibition of NPC cell viability. At a concentration of greater
than 10 lM, ApoG2 inhibited about 70% of the survival of C666-1,
CNE-1 and CNE-2 cells after 72-hr treatment. In contrast, when
HONE-1 cells were exposed to 10 or 20 lM ApoG2, no obvious in-
hibition was observed even up to 72 hr. At 72 hr, the IC50 values in
C666-1, CNE-1, CNE-2 and HONE-1 cells were 1.7 6 0.792,
2.055 6 0.711, 4.915 6 2.044 and 50.178 6 15.832 lM, respec-
tively. The relative low expression levels of antiapoptotic Bcl-2
family proteins in HONE-1 cells could in part result in the resist-
ance of HONE-1 cells to ApoG2.
ABT-737 is another small-molecule BH3 mimetic that exhibits
single-agent activity against leukemia, lymphoma and small-cell
lung cancer cells in preclinical studies. But in cancers with
increased Mcl-1 expression, ABT-737 has no obvious efficacy,
because of its inability to target this prosurvival molecule.47 In the
majority of sensitive cancer cell lines, the IC50 values of ABT-737
ranged from 40 nM to 10 lM,48 close to the IC50 values of ApoG2
in NPC cell lines. So we compared the effect of 0.1, 1.0 and
10.0 lM ABT-737 and ApoG2 on NPC cell lines. ABT-737
showed relatively lower activity against NPC cells (Fig. 2b) than
did ApoG2.
ApoG2 induces DNA fragmentation and apoptosis in NPC cells
To determine whether ApoG2 treatment could induce apoptosis
in NPC cells in vitro, we treated NPC cells with ApoG2 (10 lM)
or the DMSO control. Seventy-two hours after treatment, cells
were stained with DAPI to identify the apoptotic cell population.
Treatment with DMSO did not appreciably induce apoptosis in
NPC cells. However, typical morphological changes associated
with apoptosis–chromatin condensation, apoptotic body formation
and DNA fragmentation were prevalently observed in ApoG2-
treated C666-1, CNE-1 and CNE-2 cells; these changes were not
evident in treated HONE-1 cells (Figs. 3a and 3b). A DNA ladder
formation assay was also done to identify ApoG2-induced apopto-
sis. As shown in Figure 3c, in untreated CNE-1 cells, no DNA lad-
FIGURE 2 – Growth-inhibitory effect of ApoG2 on NPC cells. MTT assays were performed in 4 representative NPC cell lines, C666-1, CNE-1,
CNE-2 and HONE-1. (a) Effect of ApoG2 on proliferation of cells. Cells were cultured at 15,000–25,000 cells/mL in a 96-well plate, exposed
to 0–20 lM ApoG2 and incubated for 24, 48 and 72 hr. Points, average of 3 experiments; bars, standard deviation (SD). (b) Comparison of the
effects of ApoG2 and ABT-737 against NPC cells. Effects were evaluated for 0.1, 1 and 10 lM of ApoG2 or ABT-737 for 72-hr treatment. Bar,
SD.
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FIGURE 3 – Induction of apoptosis in NPC cells by ApoG2. (a) Staining by DAPI shows characteristic features of apoptosis in ApoG2-
exposed cells. On the right, C666-1, CNE-1, CNE-2 and HONE-1 cells were treated with 10 lM ApoG2 for 48 hr; thereafter, cells were stained
with DAPI and detected by fluorescence microscopy. DMSO (0.1%) solution treatment (left) served as a control. (b) The number of apoptotic-
characteristic DAPI-staining nuclei per 340 high-power field (HPF) is indicated. Numbers indicate the average for 5 HPFs per sample; data
shown are representative of 3 different experiments; bars, SD. (c) ApoG2-induced DNA fragmentation in CNE-2 cells was detected by DNA
ladder formation assay as detailed in Material and Methods. Cells were treated with 5 or 10 lM ApoG2 for 48 hr or with 10 lM ApoG2 for 24,
48 and 72 hr; thereafter, cells were harvested and DNA was isolated and separated by 0.8% agarose gel electrophoresis and visualized under UV
light. DMSO served as negative treatment (NT). (d) Propidium iodide (PI) staining and flow cytometric analysis of apoptosis in CNE-2 cells.
These representative pictures show apoptotic cells (in sub-G1 phase) generated from staining of CNE-2 cells after treatment with 0, 5 and
10 lM ApoG2 for 48 and 72 hr. Numbers on lines show the percentage of apoptotic cells. [Color figure can be viewed in the online issue, which
is available at www.interscience.wiley.com.]
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ders were detected; in contrast, the formation of DNA ladders was
detected after treatment with ApoG2 (10 lM) for 48 hr. Similar
fragmented DNA ladders with more intense DNA damage were
also obtained after exposure to ApoG2 for 72 hr. Taken together,
these experiments show that ApoG2 treatment markedly caused
the DNA fragmentation of sensitive NPC cells.
To quantify ApoG2-induced apoptosis of NPC cells, PI staining
and flow cytometry were conducted. At 72 hr after treatment,
ApoG2 (5 to 10 lM) had induced 50–90% of CNE-1, CNE-2 and
C666-1 cells to undergo apoptosis. However, only 14% of HONE-
1 cells underwent apoptosis after exposure to 20 lM ApoG2 for
72 hr (Fig. 3d and Supplementary Table). Most cells were under-
going early stages of cell death at 48 hr after treatment, so PI
staining could not detect this stage of cell death. These data indi-
cate that ApoG2 indeed induced apoptosis in all the NPC cell lines
tested except HONE-1 cells, which was consistent with the results
of the MTT growth-inhibition assay.
ApoG2 induces release of cytochrome c and activation of caspases
in NPC cells
Release of cytochrome c from the mitochondrial intermembra-
nous space into the cytosol is a prominent manifestation of apo-
ptosis. We hypothesized that ApoG2-induced apoptosis might be
mediated by the release of cytochrome c from mitochondria. As
shown in Figure 4a, cytochrome c was undetectable in the cytosol
of untreated CNE-2 cells (Lane 1), but after treatment with 10 lM
ApoG2 for 24 hr, the release of cytochrome c into the cytosol
began to be detectable (Lane 3). After treatment for 48 and 72 hr,
cytochrome c was increasingly translocated into the cytosol
(Lanes 4 and 5).
Apoptosis is always associated with the activation of specific
cysteine proteases referred to as caspases. In caspase colorimetric
assay, we found that ApoG2 treatment activated specific caspases.
As shown in Figure 4b, in CNE-2 cells, caspase-3 was activated as
early as 24 hr after exposure to 10 lM ApoG2. Spectrometry also
demonstrated that treatment of CNE-1 and CNE-2 cells with
ApoG2 for 0–72 hr resulted in increased activity of caspase-9 and
caspase-3 (Figs. 4c and 4d). The maximum increases in caspase-3
and caspase-9 activity were seen at 24 and 12 hr, respectively.
ApoG2 sensitizes NPC cells to CDDP treatment in vitro
and inhibits tumor growth in CNE-1 and CNE-2
xenografts in nude mice
Having investigated the effect of ApoG2 on NPC cell prolifera-
tion by MTT assay, we next studied the effect of ApoG2 in combi-
nation with CDDP. ApoG2 at 0.625 or 1.25 lM alone, CDDP at 2.5
lM alone and their combination (ApoG2 0.625 lM 1 CDDP 2.5
lM or ApoG2 1.25 lM 1 CDDP 2.5 lM) were tested against NPC
cell proliferation in vitro. As shown in Figure 5a, when combined
with CDDP, ApoG2 induced much greater growth inhibition than
did either ApoG2 or CDDP alone. The combination of CDDP (from
0.625 to 10 lM) and ApoG2 (from 0.3125 to 5 lM) produced a CI
value of less than 1 in C666-1, CNE-1 and CNE-2 cells. The combi-
nation of 2.5 lM CDDP and 1.25 lM ApoG2 produced CI values of
0.894, 0.721, 0.562 and 1.096 in C666-1, CNE-1, CNE-2 and
HONE-1 cells, respectively. ApoG2 (from 0.3125 to 5 lM) had little
effect on HONE-1 cells (Fig. 2a) whereas CDDP (from 0.625 to 10
lM) had a powerful effect on this cell line, it seemed that CDDP
was just an additive power to ApoG2 in this cell line. These data
indicated that CDDP and ApoG2 synergistically inhibited cell sur-
vival of ApoG2-sensitive NPC cell lines in vitro. Next, we tested
whether these 2 drugs also synergistically functioned in vivo.
ApoG2 is well tolerated in nude mice; the maximal tolerated
dose (MTD) was previously found to be greater than 480 mg/kg
by intragastric administration daily.33 In our study, when all con-
trol tumors developed to more than 1,000 mg, nude mice were
killed and xenografts were removed for weighing (Supplementary
Fig. S2). Antitumor activity measurements for CDDP alone
(3 mg/kg given intraperitoneally once every 2 days) and ApoG2
alone (200 mg/kg given by intragastric administration daily), as
measured by T/C % ratios, were 54% and 78%, respectively, in
FIGURE 4 – Activation of the mitochondrial pathway of apoptosis by ApoG2 treatment. (a) Release of cytochrome c in CNE-2 cells exposed
to ApoG2. Cells were exposed to 10 lM ApoG2 for 0–72 hr. Isolation of cytosol and mitochondrial fractions is described in Material and Meth-
ods. Proteins obtained from cytosolic fractions were separated by 12% SDS-PAGE and detected using anti-cytochrome c antibody. (b) Cleavage
of caspase-3 in ApoG2-treated CNE-2 cells. CNE-2 cells were treated with 10 lM ApoG2 for 0–72 hr. Cell lysates were subject to electrophore-
sis followed by immunoblot with caspase-3-specific antibody. (c) Activation of caspase-3 and caspase-9 in ApoG2-treated CNE-1 and CNE-2
cells. When caspase-3 and caspase-9 were activated, chromophoric groups were freed from caspase substrates and detected by spectrophotome-
try. OD values obtained by spectrophotometry represent caspase-3 and caspase-9 activity. Bar, SD.
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CNE-1 xenograft-bearing nude mice and 48% and 69%, respec-
tively, in CNE-2 xenograft-bearing mice (Fig. 5c). When com-
bined with CDDP, ApoG2 showed greater antitumor activity, with
T/C % ratios of 46% in CNE-1 xenograft-bearing mice and 29%
in CNE-2 xenograft-bearing mice. Figure 5b shows the tumor vol-
umes (mm3) of mice treated with CDDP alone, ApoG2 alone and
the combination of CDDP and ApoG2 compared with those of the
control group. In CNE-2 xenograft-bearing mice, tumor volumes
in the drug-combination group decreased significantly compared
with those of mice that received either CDDP (p 5 0.025, Fisher’s
protected least significant difference [LSD] test) or ApoG2 alone
(p < 0.001, Fisher’s protected LSD test); in CNE-1 xenograft-
bearing mice, tumor volumes in the drug-combination group
decreased significantly compared with those of mice that received
ApoG2 alone (p 5 0.009, Fisher’s protected LSD test) but not
CDDP alone (p 5 0.204, Fisher’s protected LSD test).
To determine whether ApoG2 treatment induces apoptosis of
NPC cells in vivo, tumor sections from CNE-2-bearing nude mice
were stained with TUNEL to identify the apoptotic cell popula-
tion. As shown in Figures 6a and 6b, treatment with saline solu-
tion (control) did not appreciably induce apoptosis, whereas treat-
ment with ApoG2 alone, CDDP alone or their combination stimu-
lated a substantially increased number of TUNEL-positive cells in
NPC tumors, as indicated by vacuolated and brown-nuclear cells
(arrowheads). Combined drug treatment induced more TUNEL-
positive cells than did ApoG2 alone (p5 0.002, Fisher’s protected
LSD test) or CDDP alone (p 5 0.027, Fisher’s protected LSD
test). Although these results were encouraging, the impact of the
FIGURE 5 – ApoG2’s effects on the antitumor activity of CDDP against NPC cell lines in vitro and on tumor growth of CNE-1 and CNE-2
xenografts in nude mice. (a) Effect of the combination of ApoG2 and CDDP on the growth of 4 NPC cell lines in vitro after 72 hr. Cells were
cultured at 15,000–25,000 cells/mL in a 96-well plate with or without agents. Bar heights, average of 3 experiments; bars, SD. (b) Inhibition of
tumor growth by ApoG2, CDDP or their combination in CNE-1 and CNE-2 xenograft-bearing nude mice. Saline solution treatment served as a
control. The tumor length diameter (A) and width diameter (B) were measured every 2 days. The tumor volumes were calculated as (A 3 B2)/2.
All animals were treated 3 days after tumor transplantation. *p values for treated groups were obtained by comparison with the control group.
Bar, SD. (c) Antitumor acitivity of ApoG2, CDDP and their combination in CNE-1 and CNE-2 xenograft-bearing nude mice. When all tumors
of the control group exceeded 1 g in weight, the animal experiment was terminated. Tumor growth inhibition ratios (T/C %) were calculated by
dividing the average tumor volume in the treatment group by the average tumor volume in the control group.
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FIGURE 6 – Analysis of the impact of ApoG2 and CDDP, as single agents or in combination, on cell apoptosis and Bcl-xL, PUMA and CD31
expression in vivo in CNE-2 xenografts. The tumor tissues from each group (saline solution control, ApoG2, CDDP and ApoG2 1 CDDP com-
bination) were obtained at the end of 12 days of treatment. (a) TUNEL staining of CNE-2 xenograft tumor sections after treatment. The apopto-
tic cells that had DNA fragmentation were stained positively as brown nuclei (arrowheads). Magnification, 380. (b) The number of TUNEL-
positive cells per 3 20 high-power field (HPF) is indicated. Numbers indicate the average for 5 HPFs per section. Data shown are representative
of 3 different experiments; bars, SD. (c) Bcl-xL, PUMA and CD31 immunohistologic staining of the same tumor sections as in Figure 6a for
Bcl-2 family proteins and tumor angiogenesis analysis. Magnification, 380.
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drugs on tumor-relevant biomarkers was also of great importance.
As shown in Figure 6c, ApoG2 alone and the ApoG2 and CDDP
combination did not provoke obvious changes in expression level
of antiapoptotic protein (Bcl-xL) and proapoptotic protein
(PUMA). The expression of CD31 decreased after drug treatment,
which suggested inhibition of angiogenesis in NPC xenografts.
Discussion
Antiapoptotic proteins have become attractive targets for
reversing resistance to traditional cancer treatment. Many groups
have developed various strategies for blocking the antiapoptotic
activity of Bcl-2 family proteins, including a Bcl-2 antisense oli-
godeoxynucleotide, peptides and small-molecule inhibitors.15,19
Since Bcl-2, Bcl-xL and Mcl-1 proteins function as critical apo-
ptosis regulators and important antiapoptotic molecules, it is pre-
dicted that pan-inhibition of these Bcl-2 members by small-mole-
cule inhibitors may effectively induce apoptosis in cancer cells.
The benzenesulfonamide derivative ABT-737 is a potent small-
molecule BH3 mimetic that exhibits high affinity to Bcl-2, Bcl-xL
and Bcl-w (Ki  1 nM) but not to Mcl-1 and A1 (Ki > 1 lM).19
ABT-737 has shown single-agent activity against leukemia,47
lymphoma and small-cell lung cancer in preclinical studies. How-
ever, in this study, we showed that NPC cells were not sensitive
enough to ABT-737 (Fig. 2b). Compared with MCF7 cells, NPC
cells expressed a much higher level of Mcl-1 protein (Fig. 1c),
which may explain the resistance of NPC cells to ABT-737.
Besides ABT-737, researchers have identified multiple other small
molecules with different structures.
Gossypol, a natural product isolated from cotton seeds and
roots, was used to treat patients with breast cancer49 and uterus
myoma50 before it was discovered to be a BH3 mimetic. Recently,
using multidimensional NMR methods, (2)-gossypol, the active
enantiomer of gossypol, has been conclusively shown to bind at
the BH3 groove of Bcl-xL, interacting with the same amino acid
sites in Bcl-xL as does the natural peptide Bad/Bak.33 In a fluores-
cence polarization-based binding assay, (2)-gossypol bound to
Bcl-2, Bcl-xL and Mcl-1 with Ki values of 320, 480 and 180 nM,
respectively.51
Based on the predicted binding model of (2)-gossypol, a new
series of compounds have been designed to mimic the interaction
between (2)-gossypol and Bcl-xL. One such compound is the
benzenesulfonyl derivative TW-37, which binds to Bcl-2, Bcl-xL
and Mcl-1 with Ki values of 290, 1,100 and 260 nM, respectively;
in a B-cell lymphoma xenograft model, addition of TW-37 to
standard chemotherapy results in more complete tumor inhibi-
tion.52 Furthermore, a promising analogue of gossypol, ApoG2,
has been designed by removing aldehyde groups; this analogue
has increased stability and demonstrated more potent inhibition of
Bcl-2 and Mcl-1, with Ki values of 36 and 25 nM, respectively.33
After modifications, ApoG2 contains 2 para-quinone moieties,
making the molecule a very strong electrophile that can potentially
react with cellular nucleophiles such as glutathione and cause cells
to undergo oxidative stress, which ultimately can trigger the intrin-
sic pathway and lead to apoptosis. Gossypol has been recently
found to be able to induce apoptosis by the reactive oxygen spe-
cies-dependent mitochondrial pathway in human colorectal carci-
noma cells.53 By using dichlorofluorescein diacetate (DCF-DA)
staining, we previously found that the reactive oxygen species
level was extremely low in CNE-2 cells (unpublished data).
Though ApoG2 may cause oxidative stress by depleting glutathi-
one in colorectal carcinoma and leukemia cells,47 this compound
killed NPC cells by a different molecular mechanism, by binding
to antiapoptotic Bcl-2 proteins with high affinity.
At present, there is no effective therapy in NPC treatment that
selectively kills NPC cells. In this research, we chose ApoG2, the
most potent derivative of gossypol with high affinity against Mcl-
1, Bcl-2 and Bcl-xL, to test the potential of this group of BH3-mi-
metic chemicals in NPC-targeted treatment. Data represented in
Figure 2a revealed that ApoG2 could effectively inhibit prolifera-
tion of NPC cells that expressed antiapoptotic Bcl-2 family pro-
teins at a high level. Moreover, the sensitivity of NPC cells to
ApoG2 directly correlated with their levels of expression of antia-
poptotic proteins. Although HONE-1 expressed Mcl-1, antiapop-
totic Bcl-2 and Bcl-xL levels were extremely low in this cell line
(Fig. 1c). Thus, we need to use a much higher concentration of
ApoG2 to kill HONE-1 cells. Also, there may be plenty of other
prosurvival molecules, such as c-kit/SCF,54 that prevent HONE-1
cells from undergoing apoptosis.
In vitro, ApoG2 blocked the Bcl-2/Bax (Bcl-xL/Bak) complex
and then led to activation of the mitochondrial apoptotic pathway,
including release of cytochrome c from mitochondria, activation
of caspase-3 and caspase-9 and eventually apoptotic death of NPC
cells. As shown in Figures 4c and 4d, activated caspase-3 and cas-
pase-9 increased at the early stage of cell apoptosis; after exposure
for 72 hr, activation of caspase-3 and caspase-9 was gradually
declined because most cells were dead because of apoptosis.
In NPC xenografts, we found that ApoG2 could potently sup-
press tumor growth by inducing cell apoptosis. Moreover, when
combined with CDDP, ApoG2 enhanced the antitumor activity of
CDDP in NPC cells and in CNE-2 xenografts-bearing mice (Fig.
5). In CNE-1 xenograft-bearing mice, if we continued to treat the
mice for longer periods of time, the drug resistance against CDDP
might occur and the combined treatment would significantly
decrease tumor growth. CDDP has been the first-use chemothera-
peutic drug in NPC treatment for a long time. Yet, its toxicity and
drug resistance have restricted its clinical use and therapeutic
effect. We conclude that use of ApoG2 in NPC patients may ena-
ble decreasing the dose of CDDP to attenuate its toxicity while
achieving the same or even better curative effects. In mice,
ApoG2 was given by intragastric administration at a dose of 200
mg/kg and also by intraperitoneal injection at a dose of 120 mg/kg
(data not shown). The results showed that ApoG2 was orally
effective and well tolerated; ApoG2 given by the oral route alone
and by intraperitoneal injection alone could effectively both sup-
press the growth of NPC xenografts and enhance the activity of
CDDP. This result suggests that ApoG2 could be absorbed
through both the abdominal vein and the gastrointestinal tract.
In conclusion, our study suggests that ApoG2 represents a
promising new agent that should be developed for the treatment of
NPC in humans.
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